EndoStim is a medical device company based in Dallas, Texas, and Nijmegen, The Netherlands, developing and commercializing a revolutionary treatment for gastroesophageal reflux disease (GERD).
EndoStim’s neurostimulation technology is designed to provide long-term reflux control by restoring normal esophageal function. The therapy directly targets the patient’s weak or dysfunctional lower esophageal sphincter (LES) muscle between the stomach and the esophagus, often the underlying cause of reflux. The system consists of an implantable neurostimulator and a lead that delivers low energy stimulation to the LES. The EndoStim procedure is designed to preserve natural anatomy in order to reduce or avoid typical gastrointestinal side effects of traditional anti-reflux surgery.
The EndoStim system is CE Marked for patients with gastro-esophageal reflux disease with symptom duration of six months or longer, and is available in a number of countries throughout Europe, Latin America, and Asia Pacific. The EndoStim system is not approved for sale in the US and is limited by US federal law to investigational use only.